[关键词]
[摘要]
莫西沙星(moxifloxacin)作为第四代喹诺酮类超广谱抗菌药,其最低抑菌浓度低、抗耐药特性较强,在抗结核药物中具优势和潜力。耐药结核菌群不断出现、一线药物临床疗效下降、患者顺应性差等使结核病临床治愈率低。为此,开发适合肺部介入给药的莫西沙星缓释制剂,以减少给药次数、增加患者顺应性,具有理论意义与临床价值。综述近年来出现的脂质体、微球、纳米粒子等莫西沙星缓控释制剂的国内外研究进展,为新药研发提供依据。
[Key word]
[Abstract]
Moxifloxacin (MXF) is a novel fourth generation fluoroquinolone with a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, anaerobes, and atypical organisms, the lower MIC value and high antibacterial effects make it a suitable antibiotic for treating various infectious diseases. The drug-resistant strains, the clinical efficacy decline of the first-line drugs including isoniazid and rifampicin equality, and the decreasing of resistance of patients push the therapy of the infection caused by drug-resistant strains in an embarrassing place. Therefore, it is imperative to research the MXF controlled-release preparation for pulmonary intervention therapy to decrease the dosage and improve the patient’s compliance. The paper summarizes the study progress on MXF controlled-release preparation such as liposome, microsphere, and nanoparticle, both in China and abroad.
[中图分类号]
[基金项目]
重大传染病专项(2012ZX10003009-001-002)